

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

RELEVANT EVENT

Following the Relevant Events issued on 27 October 2018 and 29 March 2019, in which Grifols shared the results of the AMBAR (Alzheimer Management by Albumin Replacement (phase IIb/III)) clinical trial, at both the Barcelona and Lisbon congresses on Alzheimer's Disease, Grifols reports that additional positive results of the clinical trial have been presented at the Alzheimer's Association International Conference (AAIC) in Los Angeles (USA).

The results are in line with the ones already announced in the above Relevant Events, in all treated groups across the different relevant end-points that combine assessment of cognitive status and daily functioning.

New updated results will be presented at the CTAD congress in San Diego (USA) in December.

In Barcelona, on 16 July 2019

Nuria Martín Barnés
Secretary to the Board of Directors